CUMBERLAND PHARMACEUTICALS (CPIX)
US2307701092 - Common Stock
CPIX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. CPIX has a bad profitability rating. Also its financial health evaluation is rather negative. CPIX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CPIX has reported negative net income.
In the past year CPIX has reported a negative cash flow from operations.
CPIX had negative earnings in each of the past 5 years.
Each year in the past 5 years CPIX had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -14.16%, CPIX is doing good in the industry, outperforming 67.02% of the companies in the same industry.
CPIX has a better Return On Equity (-43.87%) than 60.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.16% | ||
| ROE | -43.87% | ||
| ROIC | N/A |
ROA(3y)-5.94%
ROA(5y)-4.93%
ROE(3y)-14.92%
ROE(5y)-11.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 83.31%, CPIX belongs to the best of the industry, outperforming 89.53% of the companies in the same industry.
CPIX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CPIX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.31% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.02%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
CPIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CPIX has less shares outstanding
CPIX has less shares outstanding than it did 5 years ago.
CPIX has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.17, we must say that CPIX is in the distress zone and has some risk of bankruptcy.
CPIX has a Altman-Z score of 0.17. This is comparable to the rest of the industry: CPIX outperforms 51.31% of its industry peers.
A Debt/Equity ratio of 0.41 indicates that CPIX is not too dependend on debt financing.
CPIX's Debt to Equity ratio of 0.41 is on the low side compared to the rest of the industry. CPIX is outperformed by 62.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.17 |
ROIC/WACCN/A
WACC8.85%
2.3 Liquidity
A Current Ratio of 1.13 indicates that CPIX should not have too much problems paying its short term obligations.
CPIX has a worse Current ratio (1.13) than 83.25% of its industry peers.
CPIX has a Quick Ratio of 1.13. This is a bad value and indicates that CPIX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.99, CPIX is doing worse than 78.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.13 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
CPIX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -170.83%.
Measured over the past years, CPIX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.47% on average per year.
Looking at the last year, CPIX shows a decrease in Revenue. The Revenue has decreased by -6.45% in the last year.
Measured over the past years, CPIX shows a small growth in Revenue. The Revenue has been growing by 6.16% on average per year.
EPS 1Y (TTM)-170.83%
EPS 3Y14.47%
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)-6.45%
Revenue growth 3Y1.85%
Revenue growth 5Y6.16%
Sales Q2Q%-9.91%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CPIX. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CPIX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CUMBERLAND PHARMACEUTICALS
NASDAQ:CPIX (12/18/2024, 4:32:51 PM)
After market: 2.26 -0.08 (-3.42%)2.34
+0.22 (+10.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap32.85M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.16% | ||
| ROE | -43.87% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.31% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.13 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-170.83%
EPS 3Y14.47%
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-6.45%
Revenue growth 3Y1.85%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y